SRPT SECURITIES NEWS: Did Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Commit Securities Fraud? Contact BFA Law by August 25 Class Action Deadline
If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Dolgicer v. Sarepta Therapeutics, Inc., et al. , No. 25-cv-05317.
Why Was Sarepta Sued for Securities Fraud?
Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks.
In truth, Elevidys causes fatal acute liver failure in some patients.
The Stock Declines as the Truth Is Revealed
On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or over 27%, from $101.35 per share on March 17, 2025, to $73.54 per share on March 18, 2025. Nevertheless, on the same day, Sarepta assured investors that 'the benefit-risk of ELEVIDYS remains positive.'
Next, on June 15, 2025, Sarepta announced that a second patient treated with Elevidys had died from acute liver failure and that it was suspending certain shipments of Elevidys and paused dosing in an ongoing clinical trial of the treatment. On this news, the price of Sarepta stock fell $15.24 per share, or more than 42%, from $36.18 per share on June 13, 2025, to $20.94 per share on June 16, 2025.
Finally, on July 17, 2025, Sarepta revealed that a third patient treated with one of Sarepta's investigational treatments related to Elevidys had died from acute liver failure in June 2025. On this news, the price of Sarepta stock fell more than 40% on July 18, 2025.
Click here for more information: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
What Can You Do?
If you invested in Sarepta you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action
Or contact:Ross Shikowitz
[email protected]
212-789-3619
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Personalis to Announce Second Quarter 2025 Financial Results
FREMONT, Calif., July 22, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). View source version on Contacts Investors: Caroline Corner investors@ 415-202-5678 Media: pr@
Yahoo
10 minutes ago
- Yahoo
Blaize to Report Second Quarter 2025 Financial Results on August 14, 2025
EL DORADO HILLS, Calif., July 22, 2025--(BUSINESS WIRE)--Blaize (Nasdaq: BZAI, Nasdaq: BZAIW), a leader in programmable, energy-efficient edge AI computing, today announced it will release financial results for its second quarter ended June 30, 2025, on Thursday, August 14, 2025. Management will host a webcast that same day at 2:00 p.m. PT / 5:00 p.m. ET to discuss the company's financial performance and provide a business update. Event: Blaize Second Quarter 2025 Earnings Conference Call Date: Thursday, August 14, 2025 Time: 2:00 pm PT (5:00 pm ET) Live Webcast: A live webcast of the call can be accessed from the Events and Presentations page of the investor relations website, Replay: An archived conference call webcast will be available on Blaize's investor relations website for one year following the live call at About Blaize Blaize provides a full-stack programmable processor architecture suite and low-code/no-code software platform that enables AI processing solutions for high-performance computing at the network's edge and in the data center. Blaize solutions deliver real-time insights and decision-making capabilities at low power consumption, high efficiency, minimal size, and low cost. Headquartered in El Dorado Hills (CA), Blaize has more than 200 employees worldwide with teams in San Jose (CA) and Cary (NC), and subsidiaries in Hyderabad (India), Leeds and Kings Langley (UK), and Abu Dhabi (UAE). To learn more, visit or follow us on LinkedIn and on X at @blaizeinc. View source version on Contacts Investors ir@ Media info@
Yahoo
10 minutes ago
- Yahoo
Rigetti Computing to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
Rigetti Computing, Inc. BERKELEY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. ("Rigetti" or the "Company") (Nasdaq: RGTI), a pioneer in hybrid quantum-classical computing, announced today that it will release second quarter 2025 results on August 12, 2025 after market close. The Company will host a conference call to discuss its financial results and provide an update on its business operations at 5:00 p.m. ET the same day. Key details regarding the call are as follows: Call Date: Tuesday, August 12, 2025 Call Time: 5:00 p.m. ET / 2:00 p.m. PT Webcast Link: Live Call Participant Link: Webcast Instructions You can listen to a live audio webcast of the conference call by visiting the 'Webcast Link' above or the "Events & Presentations" section of the Company's Investor Relations website at . A replay of the conference call will be available at the same locations following the conclusion of the call for one year. Live Call Participant Instructions To participate in the live call, you must register using the 'Live Call Participant Link' above. Once registered, you will receive dial-in numbers and a unique PIN number. When you dial in, you will input your PIN and be routed into the call. If you register and forget your PIN, or lose the registration confirmation email, simply re-register to receive a new PIN.
